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Abstract
Background: New cancer therapeutic strategies must be investigated that enhance prostate
cancer treatment while minimizing associated toxicities. We have previously shown that genistein,
the major isoflavone found in soy, enhanced prostate cancer radiotherapy in vitro and in vivo. In this
study, we investigated the cellular and molecular interaction between genistein and radiation using
PC-3 human prostate cancer cells.
Methods: Tumor cell survival and progression was determined by clonogenic analysis, flow
cytometry, EMSA analysis of NF-κB, and western blot analysis of cyclin B1, p21WAF1/Cip1, and
cleaved PARP protein.
Results: Genistein combined with radiation caused greater inhibition in PC-3 colony formation
compared to genistein or radiation alone. Treatment sequence of genistein followed by radiation
and continuous exposure to genistein showed optimal effect. Cell cycle analysis demonstrated a
significant dose- and time-dependent G2/M arrest induced by genistein and radiation that correlated
with increased p21WAF1/Cip1 and decreased cyclin B1 expression. NF-κB activity was significantly
decreased by genistein, yet increased by radiation. Radiation-induced activation of NF-κB activity
was strongly inhibited by genistein pre-treatment. A significant and striking increase in cleaved
PARP protein was measured following combined genistein and radiation treatment, indicating
increased apoptosis.
Conclusion: A mechanism of increased cell death by genistein and radiation is proposed to occur
via inhibition of NF-κB, leading to altered expression of regulatory cell cycle proteins such as cyclin
B and/or p21WAF1/Cip1, thus promoting G2/M arrest and increased radiosensitivity. These findings
support the important and novel strategy of combining genistein with radiation for the treatment
of prostate cancer.
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Background
Prostate cancer (PCa) is an important public health con-
cern in the United States. As our population ages, the
number of patients with clinically significant PCa is
expected to increase. In the United States, PCa is the most
commonly diagnosed cancer in men as well as the second
leading cause of male cancer deaths. The American Cancer
Society estimates that in 2006 there will be 234,460 new
cases of PCa and 27,350 men will die of the disease [1].
Localized PCa is sensitive to conventional radiotherapy
using megavoltage photons (X-rays), yet residual disease
often causes clinical relapse in a large proportion of
patients [2,3]. While there is continuing debate on the
impact of various treatment modalities on the survival of
patients with different stages of PCa, the utilization of
nutrition as an adjuvant therapy is an attractive idea. The
use of dietary supplements, including soy, for cancer ther-
apy has been recently reviewed [4,5]. To improve the local
control and treatment of PCa, we have investigated the
combination of genistein with conventional radiation
treatment.
Genistein (4',5,7-trihydroxyisoflavone), the most abun-
dant isoflavone found in soybeans, is believed to be a
potent anticancer agent [6,7]. The interest in genistein
stems from observations that increased soy consumption
in Asian diets, resulting in increased serum isoflavone lev-
els, has been associated with a decreased risk for PCa [8].
Genistein has an heterocyclic diphenolic structure similar
to estrogen [9] and has demonstrated anti-tumor and
anti-angiogenic activities [10,11]. Genistein was found to
inhibit tyrosine protein kinases [12], topoisomerase I and
II [13], and protein histidine kinase [14]. Genistein has
also been shown to inhibit cell growth of tumor cell lines
from various malignancies including breast, lung,
melanoma, prostate, head and neck squamous cell carci-
noma, leukemia and lymphoma [15-22].
We have previously shown that genistein inhibited the
cell growth of androgen-dependent (LNCaP) and andro-
gen-independent (PC-3) human prostate carcinoma cell
lines [23]. Genistein affected the cell cycle and induced
apoptosis, establishing it as a cytotoxic agent for PCa. We
found that genistein induced G2/M cell cycle arrest lead-
ing to cell growth inhibition [23]. Cell growth inhibition
was observed with concomitant down-regulation of cyclin
B1, up-regulation of the p21WAF1/Cip1 growth inhibitory
protein, and induction of apoptosis [23]. We have also
demonstrated that genistein augments radiation-induced
cell killing of PC-3 prostate cancer cells in vitro [24]. Gen-
istein combined with radiation significantly inhibited
DNA synthesis, cell division, and cell growth compared to
each modality alone [24].
We have also demonstrated in vivo that genistein potenti-
ated inhibition of tumor growth by radiation in an ortho-
topic metastatic PC-3/nude mouse xenograft PCa tumor
model [25]. Genistein combined with prostate tumor irra-
diation led to a greater control of the growth of the pri-
mary tumor and metastasis to lymph nodes than genistein
or radiation alone, resulting in greater mouse survival
[25]. These results suggest the potential for combining
genistein with radiation for the treatment of localized PCa
in humans.
The goal of our present study was to further elucidate the
cellular and molecular interaction between genistein and
radiation in vitro. We have investigated the effect of genis-
tein and radiation on cell cycle progression and apoptosis
and determined the optimal dose and time kinetics of
each. We show that the potentiation of radiation-induced
cell killing by genistein was optimal with the sequence of
pre-treatment with genistein followed by radiation and
continued exposure with genistein. This effect was also
observed with other human tumor cell lines from various
malignancies, indicating that our treatment strategy is not
PCa cell-specific. The G2/M cell cycle arrest observed with
genistein was enhanced by combination with radiation.
This effect was associated with a greater up-regulation of
the p21WAF1/Cip1 growth inhibitory protein and down-reg-
ulation of cyclin B1 than that seen with genistein alone,
resulting in a significant increase in apoptosis. Moreover,
the inhibition of NF-κB DNA binding activity induced by
genistein was also enhanced by combining genistein with
radiation. We propose a mechanism of increased cell
death in PCa cells pre-treated with genistein that may be
dependent upon downregulation of radiation-induced
NF-κB, thus driving cancer cells toward apoptotic versus
survival pathways.
Methods
Tumor cell lines
The experiments were performed using the PC-3 human
prostate carcinoma tumor cell line purchased from Amer-
ican Type Culture Collection (ATCC, Rockville, MD). PC-
3 cells were cultured in F-12 K culture medium (CM) (Inv-
itrogen, Carlsbad, CA) supplemented with 7% heat-inac-
tivated fetal bovine serum, 2 mmol/L glutamine, 0.1
mmol/L non-essential amino acids, 10 mmol/L HEPES,
and 100 U/mL penicillin/streptomycin. Human breast
cancer cell line BR231 (MDA-MB-231) was purchased
from ATCC. The human renal cell carcinoma (RCC) cell
line KCI-18 was established in our laboratory from a pri-
mary renal tumor specimen obtained from a patient with
papillary RCC (nuclear grade III/IV) [26]. The human
RCC RC-2 cell line has been previously described [27].
These cell lines were cultured in Dulbecco's modified
Eagle's medium (Invitrogen, Carlsbad, CA) with 4.5 g/L
glucose supplemented with 10% fetal bovine serum, 2
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mmol/L glutamine, 10 mmol/L HEPES, 100 U/mL peni-
cillin/streptomycin and 50 µg/mL gentamicin. The cul-
tures were incubated at 37°C in a humidified 5% CO2
incubator.
Genistein treatment
Genistein was purchased from Toronto Research Chemi-
cals (North York, Ontario, Canada) and dissolved in 0.1
mol/L Na2CO3 (Sigma, St. Louis, MO) to make a 10
mmol/L stock solution. Genistein was further diluted in
CM to obtain concentrations of 15 µmol/L or 30 µmol/L.
Control cells were incubated with equivalent dilutions of
Na2CO3 in CM. Genistein treatment was administered
when cells were 70% to 80% confluent.
Radiation treatment
Cells in 15 mL tubes, T25 flasks, or T75 flasks were irradi-
ated with photons using a 60Co unit (AECL Theratron
780). Tubes were placed at a depth of 2.6 cm in a specially
machined lucite block of dimensions 10 cm × 20.3 cm ×
12.8 cm [24]. The surface of the block was positioned at
46 cm from the source and tubes were irradiated with a
horizontal 25 cm × 25 cm beam at a dose rate was -92 cGy
min-1 [24]. Flasks were irradiated from above with a verti-
cal beam, 2.5 mm of polystyrene build up material was
placed on top of the flasks and the surface of the build-up
material was at a distance of 76 cm from the source. The
dose rate was -32 cGy min-1.
Analysis of cell survival by clonogenic assay
Cells were plated in T25 flasks at 0.5 × 106 cells/flask in
CM. Three days later, 75% confluent cells were washed in
CM and treated with genistein at a final concentration of
15 µmol/L in 5 mL CM. After 24 hr exposure to genistein,
cells were removed using trypsin-EDTA (Invitrogen,
Carlsbad, CA), counted and transferred to 15 mL conical
tubes at 2 × 106 cells/5 mL CM for photon irradiation. Fol-
lowing irradiation, cells were plated in triplicate using 6-
well plates. For comparison between each treatment
group, the number of cells plated after genistein and/or
radiation treatment was adjusted relative to untreated
cells to predict a measurable survival fraction, as deter-
mined in pilot experiments. Based on these data, the
number of cells plated in 2 mL CM were as follows: 500
cells/well for control, 1000 cells/well for genistein or radi-
ation alone, and 3000 cells/well for genistein + radiation
treatments. After plating, cells in respective treatment
groups were supplemented with genistein at a final con-
centration of 15 µmol/L. Following 10–13 days incuba-
tion at 37°C in a 5% CO2/5% O2/90% N2 incubator,
colonies were fixed and stained in 2% crystal violet in
absolute ethanol, then counted. Clones of at least 50 cells
were counted as one colony. The plating efficiency was
calculated for each well by dividing the number of colo-
nies by the original number of cells plated. The surviving
fraction was normalized to control cell plating efficiency
by dividing the plating efficiency of treated cells by that of
control cells.
Analysis of cell cycle progression
PC-3 cells were plated in T25 flasks at 1 × 106 cells/flask in
CM. One day later, when 75% confluent, cells were
washed in CM and treated with genistein at a final concen-
tration of 15 µmol/L or 30 µmol/L in 5 mL CM. After 24
hr exposure to genistein, the cell monolayer in T25 flasks
was irradiated with 3 Gy photons. On day 4 post-radia-
tion, flasks were washed with Hanks' balanced salt solu-
tion (HBSS) and removed using trypsin-EDTA
(Invitrogen, Carlsbad, CA). Cells were then washed in
phosphate-buffered saline (PBS), counted and 0.5 × 106
cells/100 µl PBS buffer were fixed and permeabilized in
4.5 mL of 70% cold ethanol for 2 hr on ice. Cells were
washed again in PBS then stained for 30 min at room tem-
perature with 1 mL DNA fluorochrome solution contain-
ing 200 µg propidium iodide (Sigma, St. Louis, MO),
0.1% Triton X-100 (Sigma, St Louis, MO), and 2 mg
DNase-free ribonuclease A (Sigma, St Louis, MO). Cells
were analyzed using a FACScan flow cytometer (Becton
Dickinson, Mountain View, CA).
Analysis of protein expression by western blot
Cells were plated in T75 flasks at 1 × 106 cells/flask in CM.
Seventy-five percent confluent cells were washed in CM
then treated with genistein at a final concentration of 30
µmol/L in 10 mL CM. After 24 hr exposure to genistein,
cells were irradiated with 3 Gy photons. After 1 hr, cells
were removed using trypsin-EDTA (Invitrogen, Carlsbad,
CA) and collected by centrifugation. Nuclear and cyto-
plasmic proteins were isolated using CelLytic™
NuCLEAR™ Extraction Kit (Sigma, St. Louis, MO) accord-
ing to the manufacturer's protocol. Extracts were
aliqouted, flash frozen in liquid nitrogen, and stored at -
80°C for subsequent western blot analyses. Protein con-
centrations were determined according to Bradford using
Protein Assay Kit I (Bio-Rad, Hercules, CA).
Western analysis was performed using 20 µg nuclear
extracts as previously described [28]. Briefly, each sample
was prepared with an equal volume of 2X loading dye
(National Diagnostics, Atlanta, GA), subjected to 10%
SDS-PAGE (.75 mm thick; 30% Acrylamide/Bis Solution
29:1) and transferred to a Hybond™ ECL™ nitrocellulose
membrane (Amersham Pharmacia Biotech, Piscataway,
NJ) using a semi-dry transfer apparatus (Bio-Rad, Her-
cules, CA). SDS-PAGE progression was monitored using
dual color Precision Plus Protein™ Standards (Bio-Rad,
Hercules, CA). Upon completion of SDS-PAGE, the region
containing the protein(s) of interest was excised and pre-
pared for western analysis while the remaining portion of
the gel was stained with GelCode® Blue Stain Reagent
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(Pierce, Rockford, IL) to ensure equal quantity of protein
was loaded onto the gel. Western blot analysis was accom-
plished using manufacturer recommended dilutions of
rabbit polyclonal anti-PARP (214/215) cleavage site spe-
cific antibody (BioSource, Camarillo, CA), mouse mono-
clonal anti-cyclin B1 antibody (D-11, Santa Cruz
Biotechnology, Santa Cruz, CA), and mouse monoclonal
anti-p21WAF1/Cip1 antibody (187, Santa Cruz Biotechnol-
ogy, Santa Cruz, CA). After incubation in recommended
dilutions of goat anti-mouse IgG-HRP (Santa Cruz Bio-
technology, Santa Cruz, CA) or goat anti-rabbit IgG-HRP
(Cell Signaling Technology, Beverly, MA), membranes
were incubated in SuperSignal® West Pico Chemilumines-
cent Substrate (Pierce, Rockford, IL), exposed to CL-Xpo-
sure Film™ (Pierce, Rockford, IL) and developed using an
All-Pro 100 Plus automated X-ray film processor (All-Pro
Imaging Corporation, Hicksville, NY). Membranes were
stripped using Restore™ buffer (Pierce, Rockford, IL) and
reprobed with rabbit polyclonal anti-Rb antibody (C-15,
Santa Cruz Biotechnology, Santa Cruz, CA) and devel-
oped as described above as an additional control for
nuclear protein loading. The resultant bands were quanti-
fied using AlphaEaseFC™ imaging software (AlphaIn-
notech, San Leandro, CA).
Analysis of NF-κB DNA binding activity
PC-3 cells were treated with 30 µmol/L genistein for 24 hr
then irradiated with 3 Gy photons. After 30 min, cells
were removed using trypsin-EDTA (Invitrogen, Carlsbad,
CA) and collected by centrifugation. Nuclear proteins
were isolated as previously described [29]. Briefly, the cell
pellet was resuspended in 0.5 mL lysis buffer (10 mmol/L
Tris-HCl, pH 7.5; 5 mmol/L MgCl2; 0.05% Triton X-100)
and lysed with 20 strokes in a 1 mL Dounce homogenizer.
The homogenate was centrifuged at 10,000 g for 15 min-
utes at 4°C. The pellet was resuspended in equal volume
of nuclear extraction buffer A (10 mmol/L Tris-HCl, pH
7.4; 5 mmol/L MgCl2) and nuclear extraction buffer B (1
mol/L NaCl; 10 mmol/L Tris-HCl, pH 7.4; 4 mmol/L
MgCl2). The resuspended pellet was incubated on ice for
30 min and then centrifuged at 10,000 g for 15 min at
4°C. The supernatant containing the nuclear proteins was
removed and 80% glycerol was added to a final glycerol
concentration of 20% (vol/vol). Protein concentrations
were determined using the bicinchoninic acid (BCA) pro-
tein assay (Pierce, Rockford, IL).
NF-κB DNA binding activity was determined by electro-
phoretic mobility shift assay (EMSA) as previously
described [29]. Briefly, 10 µg nuclear extract was incu-
bated with 32P-labeled and purified NF-κB consensus
double-stranded oligonucleotide and 0.25 mg/mL
poly(dI- dC) in 5X binding buffer (20% glycerol, 5 mmol/
L MgCl2, 2.5 mmol/L EDTA, 2.5 mmol/L DTT, 250 mmol/
L NaCl, 50 mmol/L Tris-HCl, pH7.5). After incubation at
room temperature for 30 min, samples were loaded on a
pre-run 8% polyacrylamide gel and run at 30 mA for 45
min. The gel was dried, exposed to X-ray film overnight at
-80°C, then developed using an All-Pro 100 Plus auto-
mated X-ray film processor (All-Pro Imaging Corporation,
Hicksville, NY). The resultant bands were quantified using
>Effect of genistein and radiation treatment on the survival fraction of human tumo  cell linesFigure 1
Effect of genistein and radiation treatment on the 
survival fraction of human tumor cell lines. (A) PC-3 
prostate cancer cells were treated with 15 µmol/L genistein 
for 24 hr then irradiated with 2 or 3 Gy photons. After radi-
ation, cells were plated in a clonogenic assay. (B) Cells from 
the PC-3 (prostate cancer), BR-231 (breast cancer), and KCI-
18 and RC-2 (renal cell carcinoma) cell lines were treated 
with 15 µmol/L genistein for 24 hr then irradiated with 3 Gy 
photons and plated in a clonogenic assay. Colonies were 
stained with crystal violet and counted after 11–13 days incu-
bation. The mean survival fraction ± S.E.M. of triplicate wells 
was normalized to control cells based on plating efficiency. 
(*): value statistically significant from control at p < 0.05. 
Combined treatment was significantly greater (p < 0.05) than 
genistein or radiation alone.
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AlphaEaseFC imaging software (AlphaInnotech, San
Leandro, CA). Anti-Rb immunoblotting with nuclear pro-
tein was performed as a loading control as described
above.
Statistical analysis
Comparisons of survival fractions in the clonogenic assays
among the various treatment groups were analyzed by
two-tailed unpaired Student's t-Test. Comparisons
between means in the western blot and EMSA assays
among the various treatment groups were analyzed by
two-tailed Student's t-Test for independent samples. A p-
value less than 0.05 was considered statistically signifi-
cant.
Results
Enhanced cell growth inhibition of prostate carcinoma 
cells and other tumor cell lines by genistein and radiation
Doses of 15 µmol/L genistein and 3 Gy radiation were
selected based on previous dose titration experiments
[24]. Treatment of PC-3 cells with 15 µmol/L genistein or
3 Gy radiation alone promoted approximately 50% inhi-
bition in cell growth, while optimal cell killing was
observed after pre-treatment with 15 µmol/L genistein
combined with low-dose photon radiation [24]. To con-
firm this observation, we have repeated the clonogenic
assay with an adjusted number of cells plated after genis-
tein and/or radiation treatment in order to predict a meas-
urable survival fraction that permitted enhanced
comparisons between single and combined treatments
(see Methods section). PC-3 cells were treated with 15
µmol/L genistein for 24 hr then irradiated with 2 Gy or 3
Gy photon radiation. To evaluate the long-term effect of
the single or combined treatments, cells were plated in a
10 day clonogenic assay in the presence of 15 µmol/L gen-
istein. Genistein augmented cell growth inhibition
induced by 2 Gy or 3 Gy radiation to 72% (p < 0.005) and
80% (p < 0.001), respectively compared to 55% and 65%
with 2 Gy or 3 Gy radiation alone; whereas, genistein
alone caused only 40% inhibition (Fig. 1A). Based on
these data, the conditions of 15 µmol/L genistein and 3
Gy photon radiation were selected for continuation of the
studies.
To assess whether the potentiation of radiation-induced
cell killing by pre-treatment with genistein is not a phe-
nomenon restricted to PC-3 cells, additional human
tumor cell lines were tested (Fig. 1B). The response of PC-
3 cells to genistein and radiation was compared to the
human breast cancer cell line MDA-MB-231 (BR231) and
also two renal cell carcinoma cell lines KCI-18 and RC-2.
Cells were pre-treated with 15 µmol/L genistein for 24 hr,
then irradiated with 3 Gy photon radiation and plated in
a clonogenic assay in the presence of 15 µmol/L genistein.
BR231, KCI-18 and RC-2 cell lines showed a comparable
inhibition of cell growth when treated with genistein
alone, but a lower response to radiation compared to PC-
3 cells (Fig. 1B). However, the genistein combined with
radiation caused a significant increase in inhibition of col-
ony formation (73–80%, p < 0.05) compared to genistein
(33–47%, p < 0.05) or radiation alone (40–50%, p < 0.05)
in the three cell lines as observed for PC-3 cells (Fig. 1B).
Sequence and exposure of genistein and radiation 
treatment
To address the effect of the sequence and exposure of gen-
istein relative to radiation, we have either pre-treated PC-
3 cells with 15 µmol/L genistein for 24 hr followed by 3
Gy photon irradiation or pre-treated the cells with radia-
tion and after 24 hr, treatment with 15 µmol/L genistein
for 24 hr. Cells were then plated for the clonogenic assay
in the presence or absence of 15 µmol/L genistein for 10
days. The sequence of genistein followed by radiation
showed a greater cell growth inhibition with continuous
exposure to genistein (88%, p < 0.05) than in the absence
of genistein in the clonogenic assay (82%) (Fig. 2A,B).
The effect of genistein alone was also more pronounced
with continued exposure (55% inhibition vs. 40% with-
out genistein, p < 0.05); whereas, the effect of radiation
remained at the level of 68% inhibition (Fig. 2A,B). This
sequence of genistein followed by radiation showed a
greater effect on cell growth inhibition than the reverse
sequence of radiation followed by genistein (p < 0.05)
(Fig. 2C,D). Even in this reverse sequence, the effect of
genistein alone or combined with radiation was greater
with continued exposure of the cells to genistein com-
pared to radiation alone and genistein + radiation (p <
0.05) (Fig. 2C,D).
Analysis of cell cycle progression after treatment with 
genistein and radiation in PC-3 cells
To investigate the molecular mechanism involved in
potentiation of radiation-induced cell killing by genistein,
we analyzed cell cycle progression and expression of mol-
ecules known to affect cell cycle regulation. PC-3 cells
were treated for 24 hr with 15 µmol/L or 30 µmol/L of
genistein then irradiated with 3 Gy photons. On Day 3
and 4 after radiation, separate flasks of cells were proc-
essed for DNA content and cell cycle analysis as described
in the Methods section. From Day 3 after radiation,
changes were observed in cell cycle analysis induced by
genistein, radiation or both combined, showing an
increased trend of cells in G2/M (Fig. 3A–D). Cell arrest in
G2/M phase was more prominent by Day 4 after radiation
(16%, Fig. 3J) and with a higher dose of 30 µmol/L genis-
tein (31%, Fig. 3K) compared to 9% in control cells (Fig.
3I). Cells treated with genistein and radiation showed a
further increase to 41% cells in G2/M cells (Fig. 3L) and a
concomitant decrease in cells in G0/G1 phase from 84% to
53% (Fig. 3L). An increase in pre-G0/G1 peak of apoptotic
BMC Cancer 2006, 6:107 http://www.biomedcentral.com/1471-2407/6/107
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cells was also noted (arrow, Fig. 3L). The percentage of
cells in S phase remained at the level of 6–8%.
Based on these data, we measured the expression of
p21WAF1/Cip1 and cyclin B1, two molecules involved in cell
cycle progression. For these short-term molecular studies,
and those described below, PC-3 cells were treated with
30 µmol/L genistein for 24 hr, followed by 3 Gy irradia-
tion and processed for extraction of nuclear and cytoplas-
mic proteins at 1 hr post-irradiation. Following genistein
and radiation, the expression of p21WAF1/Cip1 showed a
1.5-fold increase in nuclear expression associated with
26% decrease in cytoplasmic expression (Fig. 4A). This
pattern was comparable to that observed with genistein
alone, although at a lower extent (1.1-fold increase in
nuclear expression) (Fig. 4A). In contrast, radiation alone
showed an significant increase in the expression of
p21WAF1/Cip1 protein both in the nuclear and cytoplasmic
fractions (Fig. 4A). Genistein combined with radiation
caused a 55% decrease in cyclin B1 expression in the cell
nucleus compared to control cells (Fig. 4B). This decrease
was greater than that observed with genistein alone (14%
at 24 hr post-treatment) (Fig. 4B). No striking effect was
observed with radiation alone when cells were tested at 1
hr post-radiation.
Inhibition of radiation induced NF-κB activation by pre-
treatment with genistein and induction of apoptosis in PC-
3 cells
We have previously demonstrated that apoptosis induced
by genistein alone in PC-3 cells was associated with a
decrease in NF-κB DNA binding activity [29], a well-
known transcription factor critically involved in the sur-
vival of cells. Preliminary studies showed that radiation at
3 Gy or 5 Gy of PC-3 cells caused increased NF-κB DNA
binding activity detectable by 30 min post-radiation, per-
sisted up to 3 hr post-radiation, and then a decrease was
observed. Based on these data suggesting that activation of
NF-κB was an early event in response to radiation, the
conditions for testing NF-κB activity in cells treated with
genistein and radiation were selected. Cells were treated
with 30 µmol/L genistein for 24 hr, followed by 3 Gy irra-
diation and harvested at 30 min post-radiation and
nuclear proteins were extracted for EMSA analysis of NF-
κB DNA binding activity. An significant increase (23%, p
< 0.0009) in NF-κB was observed at 30 min post-irradia-
tion whereas genistein-treated cells exhibited a significant
decrease (21%, p < 0.0015) in NF-κB DNA binding activ-
ity (Fig. 5A). Pre-treatment of PC-3 cells with genistein for
24 hr followed by radiation showed that NF-κB DNA
binding activity was significantly inhibited (66%
decrease, p < 0.00004) (Fig. 5A). This NF-κB DNA binding
inhibition induced by genistein combined with radiation
persisted for 1 hr and 3 hr post-radiation (data not
shown), suggesting its mechanistic role for enhanced
apoptosis. Furthermore, the inhibition of NF-κB DNA
binding activity by genistein and radiation was consistent
with western blot analysis, with these cells showing a 21%
increase in NF-κB p65 cytoplasmic protein expression
compared to control, untreated cells (data not shown).
To test whether the increased NF-κB DNA binding inhibi-
tion observed in PC-3 cells treated with genistein and radi-
ation resulted in increased apoptosis, we analyzed the
Determination of the most effective combined treatment sequence in PC-3 cellsFig e 2
Determination of the most effective combined treat-
ment sequence in PC-3 cells. PC-3 cells were analyzed by 
clonogenic assay to determine the most effective combined 
genistein + radiation treatment sequence. (A) PC-3 cells 
treated with 15 µmol/L genistein for 24 hr then irradiated 
with 3 Gy photons and plated in clonogenic assay. (B) PC-3 
cells treated with 15 µmol/L genistein for 24 hr then irradi-
ated with 3 Gy photons, followed by plating and continued 
treatment with 15 µmol/L genistein throughout clonogenic 
assay. (C) PC-3 cells irradiated with 3 Gy photons and 24 hr 
later treated with 15 µmol/L genistein for 24 hr then plated 
in clonogenic assay. (D) PC-3 cells irradiated with 3 Gy pho-
tons, and after 24 hr treated with 15 µmol/L genistein for 24 
hr followed by plating and continued treatment with 15 
µmol/L genistein throughout clonogenic assay. The colonies 
were stained and counted after 10 days incubation at 37°C in 
a 5% CO2/5% O2/90% N2 incubator. Data are presented as 
the mean survival fraction (± S.E.M.) of triplicate wells as nor-
malized to control cells based on plating efficiency. (*): value 
statistically significant from control at p < 0.05.
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expression of the 85-kDa cleaved PARP protein, a marker
for detecting apoptotic cells. Cells were treated with 30
µmol/L genistein for 24 hr, followed by 3 Gy irradiation
and processed for extraction of nuclear proteins at 1 hr
post-irradiation. Cleaved PARP expression was signifi-
cantly and strikingly enhanced by genistein combined
with radiation as demonstrated by a 5.6-fold (p < 0.0002)
increase in expression compared to 3.6-fold (p < 0.0002)
with radiation alone and 1.8-fold (p < 0.004) with genis-
tein alone, relative to control (Fig. 5B).
Discussion
The use of soy isoflavones to potentiate conventional can-
cer treatment is a promising area for investigation. Our
laboratory has previously shown that pre-treatment with
genistein, the major isoflavone in soy, enhanced radia-
tion-induced cell killing of PC-3 human PCa cells in vitro
[24]. In the current study, we investigated the mechanism
of interaction between genistein and radiation in vitro at
the cellular and molecular levels. Using a highly cali-
brated clonogenic assay, we confirmed our previous find-
ings [24] showing that genistein combined with radiation
caused 80% inhibition in the cell survival fraction com-
pared to 40% with genistein at 15 µmol/L and 65% with
3 Gy photon radiation. Furthermore, we have demon-
strated that the combination of genistein and radiation
caused greater cell killing in both human breast and renal
cancer cell lines than each modality alone, suggesting that
this effect was not restricted to PC-3 cells and that this
combined modality may also be applied towards the
treatment of other cancers. To get an optimal effect, con-
tinuous exposure of the cells to genistein before and after
radiation was needed. Our data indicate that the sequence
of genistein followed by radiation and continuous expo-
sure of genistein result in the most effective conditions for
the combined cancer treatment.
We have previously shown that genistein treatment of PC-
3 cells resulted in G2/M cell cycle arrest and altered the
expression of two cell cycle regulatory proteins, the cyclin-
dependent kinase (CDK) inhibitor p21WAF1/Cip1 and cyclin
B1 [23]. Cell cycle analysis confirmed that either genistein
or radiation alone promote a decrease in the percentage of
cells in G0/G1 and a concomitant increase in the percent-
age of cells in G2/M. A more significant G2/M cell cycle
arrest was induced by pre-treatment with genistein fol-
lowed by radiation compared to each modality alone, an
effect which was both dose- and time-dependent. Cells
respond to DNA damaging agents by activating cell-cycle
checkpoints. Both genistein and radiation were independ-
ently found to cause late G2/M cell accumulation measur-
able 4 days after treatment in the current study and in
previous studies [23,30]. Cells in the G2/M phase of the
cell cycle have been shown to be more radiosensitive than
cells in other phases of the cell cycle [30,31]. Pre- treat-
ment with genistein does arrest cells in G2/M phase and
thus could increase their radiosensitivity resulting in
increased cell killing in addition to the direct cytotoxic
effects of genistein and radiation. This interaction is in
direct agreement with our observation that increased kill-
ing is optimal with the sequence of genistein pre-treat-
ment followed by radiation compared to the reverse
sequence.
The cell cycle regulatory molecule p21WAF1/Cip1 is a mem-
ber of Cip/Kip family of cyclin-dependent kinase inhibi-
tors (CKIs) involved in cell cycle and apoptosis regulation
[32-34]. Under cellular stress, p21WAF1/Cip1 expression is
increased through p53-dependent and -independent
pathways [34]. As shown in our studies, genistein or radi-
ation alone induced upregulation of p21WAF1/Cip1 protein
in PC-3 cells, although they are p53 defective [35]. More-
over, higher nuclear expression concomitant with
Cell cycle analysis of PC-3 cells treated with genistein and radiationFigure 3
Cell cycle analysis of PC-3 cells treated with genistein 
and radiation. PC-3 cells were treated with either 15 
µmol/L or 30 µmol/L genistein for 24 hr, 3 Gy photon radia-
tion, or 15 µmol/L or 30 µmol/L genistein for 24 hr followed 
by 3 Gy photon radiation. On days 3 and 4 post-radiation, 
cells were processed for DNA content and cell cycle pro-
gression was analyzed by flow cytometry. (Arrow in Fig. 3L): 
indicates pre-G0/G1 apoptotic peak.
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decreased cytoplasmic p21WAF1/Cip1 expression were found
in genistein pre-treated PC-3 cells exposed to radiation,
suggesting nuclear translocation. Previous studies have
shown that increased levels of p21WAF1/Cip1 in the nucleus
led to inhibition of CDKs through its binding to the cyc-
lin/CDK complexes including cyclin B/CDK complex [32-
34]. The cyclin B1/CDK1 (also known as cdc2) complex is
essential for progression of the cells through mitosis,
therefore a decrease in cyclin B proteins can result in G2/
M arrest [36]. Our data showed a greater decrease in
nuclear cyclin B1 in PC-3 cells treated with genistein com-
bined with radiation, whereas radiation did not affect cyc-
lin B1 (when measured at 1 hr post-radiation).
Our findings on G2/M arrest in response to radiation com-
bined with genistein in PC-3 cells corroborate previous
studies in DU145 human prostate cancer cells [37] and in
cervical cancer cells [38]. Our studies further address the
role of the transcription factor NF-κB in the mechanism
by which genistein enhances radiation-induced cell kill-
ing. Recent studies have shown that NF-κB, a major sign-
aling molecule involved in the regulation of cellular
proliferation and apoptosis [39-41], is constitutively acti-
vated in PCa and correlates with disease progression
[42,43]. NF-κB promotes malignant behavior by sup-
pressing apoptosis and stimulating transcription of pro-
teins involved in cell cycle progression. NF-κB activation
and nuclear translocation can lead to the synthesis of mol-
ecules critical for cell survival in response to stress. We and
others have demonstrated that genistein inhibits the acti-
vation of NF-κB in multiple cancer cell lines [15], includ-
ing PC-3 and LNCaP prostate cancer cells [29].
Furthermore, genistein pre-treatment abrogated the acti-
vation of NF-κB by the chemotherapeutic agents docetaxel
or cisplatin [44]. Such an effect is demonstrated in our
current study showing that genistein pre-treatment also
completely inhibited radiation-induced activation of NF-
κB. We also observed an increase in NF-κB p65 protein in
the cytoplasm of cells treated with genistein and radia-
tion, suggesting that NF-κB may not be translocated into
the nucleus as we have shown in previous studies with
genistein alone [29]. Recent studies have established a
correlation between radioresistance of breast cancer cells
and induction of both NF-κB and cyclin B1 and demon-
strated that fractionated radiation induced cyclin B1
expression via an NF-κB-dependent mechanism [45]. The
cyclin B1 decrease that we observed following genistein
combined with radiation could be related to the inhibi-
tion of NF-κB DNA binding activity.
Recent studies have also demonstrated that p21WAF1/Cip1
was induced in S/G2/M phases and correlated with NF-κB
activation [46]. Our findings on the effect of radiation
alone causing upregulation of p21WAF1/Cip1, G2/M arrest
and NF-κB activation could follow the same pathway.
However, the effect of genistein combined with radiation
on induction and nuclear translocation of p21WAF1/Cip1, in
addition to the observed increase in cells arrested in G2/M
phase, may not occur via an NF-κB-dependent mecha-
nism, as NF-κB DNA binding activity was in fact inhibited
by the combined treatment. The association between NF-
κB inhibition and the upregulation and nuclear transloca-
tion of p21WAF1/Cip1 induced by genistein combined with
radiation remains to be elucidated.
We propose a mechanism of increased cell killing by com-
bined genistein and radiation treatment that is triggered
by inhibition of NF-κB leading to altered transcription of
regulatory cell cycle proteins such as cyclin B and/or
p21WAF1/Cip1, thus promoting apoptotic cell death.
Increased apoptotic cell death was confirmed by the
observation of significantly elevated expression levels of
cleaved PARP protein in cells treated with genistein and
radiation, compared to each modality alone, demonstrat-
ing increased apoptotic cell death.
Conclusion
Our current findings are consistent with the hypothesis
that genistein pre-treatment sensitizes cancer cells to radi-
Effect of genistein and radiation treatment on p21WAF1/Cip1 and cyclin B1 expression in PC-3 cellsFigure 4
Effect of genistein and radiation treatment on 
p21WAF1/Cip1 and cyclin B1 expression in PC-3 cells. 
PC-3 cells were treated with 30 µmol/L genistein for 24 hr 
then irradiated with 3 Gy photons. Nuclear and cytoplasmic 
proteins were extracted 1 hr post-radiation. The relative 
level of (A) p21WAF1/Cip1 and (B) cyclin B1 protein in 20 µg 
of nuclear extract was determined by western blot analysis. 
Data are presented as the mean integrated density value 
(I.D.V.) of 3 separate experiments (± S.E.M.). (Con): control, 
untreated-cells; (Rad): cells irradiated with 3 Gy photons; 
(Gen): cells treated with 30 µmol/L genistein; (Gen + Rad): 
cells pre-treated with 30 µmol/L genistein for 24 hr then 
irradiated with 3 Gy photons. Retinoblastoma protein (Rb) 
was used as a nuclear protein loading control. (*): nuclear 
value statistically significant from control at p < 0.05; (**): 
cytoplasmic value statistically significant from control at p < 
0.05.
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ation-induced growth inhibition and apoptosis. We have
also obtained similar results in recent studies demonstrat-
ing that genistein pre-treatment potentiates chemother-
apy-induced tumor cell death both in vitro and in vivo [47-
50]. Taken together, our studies demonstrate an impor-
tant and novel strategy of combining conventional cancer
treatment with nutrition and support the use of soy isofla-
vones in combination with radiation for the treatment of
patients with prostate cancer.
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